Comparing GLP-1 Medications: How to Actually Choose

By Alsen Walker · Editorially reviewed on 25 August 2026 · Not medically reviewed by a clinician

Most comparisons between these medications are made on the wrong basis. People arrive wanting to know which is strongest, and the honest answer is that the trials people quote were never designed to be compared against each other. What actually decides it for nearly everyone is coverage, your other approved indications, and individual tolerance.

Same molecule, different brand

The commonest confusion. Several products contain identical active ingredients under different names for different approved uses, with different dose ranges and entirely separate coverage.

Your insurer treats them as different products. That is why one may be covered and the other refused, and why a prior authorization for one says nothing about the other.

Never take two products containing the same active ingredient in the same period.

Different molecules

Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on GLP-1 and GIP receptors. That dual action is the genuine pharmacological difference, and what it means for any individual is less settled than confident comparisons suggest.

There is no reliable dose equivalence between them. Switching means starting where your prescriber decides and titrating, not converting.

Against other drug classes

Phentermine is a stimulant approved for short-term use. Contrave works on appetite and reward pathways and carries contraindications that matter a great deal to some people, including anyone taking opioids. Metformin produces modest weight effects and is not approved for weight management.

Each has a role, and cost and coverage often decide between them more than efficacy does.

Against surgery

Not competing options so much as different tools. Surgery is a one-time procedure with permanent anatomical change and lifelong monitoring. Medication works while you take it. Increasingly the two are used together rather than instead of each other.

Choosing for a specific condition

Where you have an approved indication beyond weight management, that frequently decides both the clinical choice and the coverage. Cardiovascular risk reduction and obstructive sleep apnea are the two that have changed access most.

Investigational compounds

Retatrutide and orforglipron attract attention and are not approved medicines. Anything sold under those names outside a clinical trial is not a regulated product.

How to actually decide

Check your formulary for each candidate before the conversation, since coverage is the practical constraint more often than anything clinical.

Tell your prescriber every condition you have, because an indication you have not thought about may determine both suitability and payment.

Ask what happens if the first choice is not tolerated. Knowing there is a second option makes the first easier to start.